InvestorsHub on MSN
BioAffinity Technologies receives Japanese patent allowance for CyPath Lung AI diagnostic test
The Japanese Patent Office has signalled its intention to grant patent protection for bioAffinity Technologies’ noninvasive ...
Affinity Technologies receives Japanese patent for CyPath Lung test to detect lung cancer early: San Antonio Saturday, October 10, 2026, 13:00 Hrs [IST] bioAffinity Technologie ...
Lung cancer remains one of the malignancies with the highest incidence and mortality worldwide. Clinical practice has long been plagued by core dilemmas, including insufficient sensitivity in early ...
Affinity Technologies, Inc. ( (BIAF)) has issued an update. On October 8, 2026, bioAffinity Technologies announced that the Japan Patent Office issued a Notice of Allowance for a patent covering its ...
Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung Presentation to address current challenges in pulmonary nodule management and to discuss ...
SAN ANTONIO, October 08, 2026--bioAffinity Technologies receives notice of allowance for new patent in Japan covering its noninvasive CyPath Lung diagnostic test for lung cancer.
Data presented at the 2026 AACR Annual Meeting demonstrated the promise of blood-based lung cancer detection via SimpleScreen Lung. Developers designed SimpleScreen Lung as an artificial intelligence ...
Affinity Technologies (Nasdaq: BIAF) soars after the Japan Patent Office issues a Notice of Allowance for its CyPath Lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results